Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Financing Activities (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Cash from Financing Activities for 14 consecutive years, with $219000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 48.23% year-over-year to $219000.0, compared with a TTM value of $14.4 million through Dec 2025, up 1434.79%, and an annual FY2025 reading of $14.4 million, up 1434.79% over the prior year.
  • Cash from Financing Activities was $219000.0 for Q4 2025 at Heron Therapeutics, down from $13.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $154.7 million in Q2 2021 and bottomed at -$637000.0 in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $15.0 million, with a median of $371000.0 recorded in 2023.
  • Peak annual rise in Cash from Financing Activities hit 105652.11% in 2022, while the deepest fall reached 172.14% in 2022.
  • Year by year, Cash from Financing Activities stood at $487000.0 in 2021, then fell by 9.86% to $439000.0 in 2022, then tumbled by 54.67% to $199000.0 in 2023, then soared by 112.56% to $423000.0 in 2024, then crashed by 48.23% to $219000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for HRTX at $219000.0 in Q4 2025, $13.4 million in Q3 2025, and $781000.0 in Q2 2025.